PHARMACOECONOMICS IN SLOVAKIA XXXV.

Transcription

1 Slovak Society for Pharmacoeconomics member of Slovak Medical Society WHO Office in Slovakia Faculty of Healthcare Alexander Dubček University of Trenčín ISPOR Chapter Slovakia Czech Pharmacoecnomic Society Slovak Society of Clinical Pharmacology scientific conference PHARMACOECONOMICS IN SLOVAKIA XXXV. Slovak and Czech pharmacoeconomic conference XII. The conference is devoted to prof. Holomáň 70 th Pharmacoeconomic and Health Technology Assessment in the Reality of Drug and Health Policy in Slovak Republic and Czech Republic Bratislava, Congress Hall of the Ministry of Health, Slovak Republic June 13, 2018

2 Programme Registration pening PharmDr. Martin Višňanský, MBA, PhD., MSc. Slovak Society for Pharmacoeconomics, Chairman Block I. PharmDr. PhDr. Matej Petrovič, Director general Department of Pharmacy and Drug Policy, Ministry of Health Dr. Tatul Hakobyan WHO Representative to the Slovak Republic MUDr. Jana Skoupá Czech Pharmacoeconomics Society, Chairman Spotlights in drug and health policy I. 1. Spotlights in Slovak drug policy Matej Petrovič, MoH SR 2. Potential of science and research for exploitality in drug and health policy Stanislav Špánik, Deputy minister, MOH SR 3. Position of pharmacoecnomics and health technology assessment in WHO Tatul Hakobyan, WHO Representative to the Slovak Republic 4. Spotlights in Czech drug policy Jana Skoupá, Czech Pharmacoeconomic Society Coffee, tea, water Block II. Spotlights in drug and health policy II. 5. Should be the clinical pharmacologist also the pharmacoeconomics? Jozef Holomáň, Institute of Pharmacology, Clinical and Experimental Pharmacology Medical Faculty, Slovak Medical University, Bratislava 6. Ethical point of view on drug access Jozef Glasa, Institute of Pharmacology, Clinical and Experimental Pharmacology Medical Faculty, Slovak Medical University, Bratislava 7. e-health and drugs Ján Tomášik, National Health Information Center, SR

3 8. Managed entry agreement as new phenomenon in drug policy in Slovak Republic Mária Bucek Pšenková, Pharm-In, Bratislava 9. Managed entry agreement in Central and East European Countries Jiří Klimeš, Czech Pharmacoeconomic Society 10. HTA of drug for rare diseases the Czechoslovak point of view and inspirations in Europe Tomáš Doležal, Czech Pharmacoeconomic Society 11. The most important world trends in pharmacoeconomics in 2018 Martin Višnanský, Slovak Society for Pharmacoeconomics 12 min J u b i l e e r a u t prof. MUDr. Jozef Holomáň, CSc. 70 th Allocutions prof. MUDr. Jozef Glasa, CSc., PhD, vice-president, Slovak Medical Society MUDr. Jana Skoupá, MBA, Chairman, Czech Pharmacoeconomic Society PharmDr. Martin Višňanský, PhD., MBA, Chairman, Slovak Society for Pharmacoecnomics Award Personal congratulations Block III. Economy and economics 12. Theory of chaos in economy and its possible aplication to health care system Karolina Hoffmannová, Slovak Society for Pharmacoeconomics 13. Direct costs as implication of drug adverse effects Anna Lukáčová, Dôvera, Health Insurance Company 14. Pharmacoeconomy as an unique example of economy application in public sector Tomáš Mlčoch, Czech Pharmacoeconomic Society

4 Block IV. Biologicals and biosimilars 15. Current position of biosimilars and methodological aspects of real evidence their outcomes in clinical practice focusing on Czech Republic Jana Skoupá, CZECHTA Institute. Czech Republic 16. Biologicals and biosimilars in Slovak Republic in evaluation of their expenditure trends Ľubica Hlinková, Ľudmila Krč-Jediná, General Health Insurance Company 17. Biologicals and biosimilars in clinical practise point ov view Ľubomír Jurgoš, Slovak 18. Biosimilars from patients point of view Petra Balážová, Association for the Protection of Patients claims Dominik Tomek, Slovak Society fo Pharmacoecnomics, Slovak Medical University 19. Queries of biological treatment David Vetchý, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno Katarína Smolková, Slovak Society fo Pharmacoecnomics Block V. V a r i a 20. Can health technology assessement and data analyses to be science and data capture can to be research? Elena Marušáková, M&C Consulting Group, Bratislava 21. Analysis of high innovative medicinal products system in Czech Republic pros and cons Tomáš Mlčoch, Tomáš Doležal, Value Outcomes, Czech Republic 22. Do the sreeening programmes their own lives? or they should be managed? Screening programme of thyreopathies in pregnancy after 5 years (2016) from the first evaluation (2011) Ján Bielik, Faculty of Health, Alexander Dubcek University in Trencin, Slovak Republic Vladimira Kmečová, Health Insurance Company Dôvera, Bratislava, Slovak Republic Matej Bielik, KAMEAT, Ltd., Endocrinological out patients department, Nové Mesto nad Váhom, Slovak republic Marián Faktor, Health Insurance Company Dôvera, Bratislava, Slovak Republic Conclusion doc. MUDr. Ján Bielik, CSc. vice-chairman, Slovak Society for Pharmacoecnomics

5 The Accreditation Council of Slovakia for Continuous Medical Education awarded the event 7 credits. Participation in the conference is free of charge, refreshments including lunch will also be provided free of charge. Registration for the conference is possible only online via Scientific Committee Chairman: assoc.prof. Ján Bielik, MD, CSc. Members: prof. Mgr. Viliam Foltán, CSc., PharmDr. Martin Višňanský, MBA, PhD., MSc., PharmDr. Dominik Tomek, MPH, PhD, RNDr. Mária Pšenková, MPH, PhDr. Iveta Matišáková, PhD, PhDr. Katarína Gerlichová, PhD, RNDr. Zdenka Krajčovičová, PhD Organizing Committee Chairman: doc. MD. Ján Bielik, CSc. Members: Ing. Terézia Čögleyová, Ing. Mária Halgošová